Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Genenta Science
Milan, Italy
B
1-10 Employees
2014
Key takeaway
Genenta is a clinical-stage biotechnology company focused on developing innovative cell-based therapies for cancer, including solid tumors. Their lead product, Temferon™, aims to enhance the effectiveness of immunotherapies by targeting the tumor microenvironment and addressing intrinsic immunological resistance that limits the success of treatments like CAR-T cell therapies.
Reference
Core business
Genenta science | Genenta science
Takis
Rome, Italy
B
11-50 Employees
2009
Key takeaway
Takis is a Biotechnology Company with extensive experience in drug discovery, particularly in oncology. Their main focus is on developing therapeutic cancer vaccines targeting tumor antigens, which is relevant to advancements in CAR-T cell therapy.
Reference
Core business
About us
Alia Therapeutics
Italy
B
1-10 Employees
2018
Key takeaway
Alia Therapeutics is focused on developing next-generation gene editing medicines aimed at curing rare genetic diseases by directly correcting genetic errors in patients' cells.
Reference
Core business
Our company - Alia Therapeutics
Alia Therapeutics Srl is an Italian biotech start-up which mission is to develop innovative treatments for incurable genetic diseases using gene editing technology.
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
CellPly
Bologna, Italy
B
11-50 Employees
2013
Key takeaway
Cellply is focused on developing analytical tools that enhance the rapid and effective creation of cancer cell therapies, including CAR-T cell therapy. Their expertise spans various technologies, which supports innovation in the field of immunology and cancer treatment.
Reference
Core business
Cellply
Altheia Science
Milan, Italy
B
1-10 Employees
2017
Key takeaway
AurorA-TT is focused on innovative gene therapy approaches, particularly in the context of cancer and autoimmune diseases. Their research includes the identification of tumor-specific antigens and genetic mutations that could enhance targeted therapies and improve patient diagnosis and risk stratification.
Reference
Core business
Altheia Science: Towards curative medicine
Our Mission is transforming the life of patients with autoimmune diseases throught innovative and curative cell and gene therapies.
Dario Castagno and RASNA Extra Virgin Olive Oil
Italy
B
1-10 Employees
-
Key takeaway
Rasna Therapeutics is dedicated to developing innovative therapies for acute myeloid leukemia (AML) and other leukemias, highlighting their commitment to addressing significant unmet medical needs in this area.
Reference
Core business
Welcome | Rasna Therapeutics
Checkmab S.r.l.
Milan, Italy
B
1-10 Employees
2018
Key takeaway
CheckMab is focused on developing innovative immunotherapeutic strategies that selectively target and deplete tumor-infiltrating regulatory T cells (Treg cells), which may contribute to the advancement of cancer treatments. Their approach aligns with the growing interest in targeted therapies for immune-mediated diseases.
Reference
Core business
Checkmab | Sviluppo di immunoterapie contro i tumori
Transactiva srl
Udine, Italy
B
1-10 Employees
2001
Key takeaway
Transactiva is a biotech company with expertise in molecular biology and genetic engineering. They focus on industrial research and development, showcasing innovative products like LenEasy®, a soothing active for cosmetics.
Reference
Core business
The Company
Immuno Spark
Pomezia, Italy
B
251-500 Employees
-
Key takeaway
Immunospark specializes in high-quality diagnostic solutions in the Immunology and Molecular Diagnostics fields, emphasizing their commitment to integrated diagnostic formats. With two decades of experience, the company focuses on developing new products and solutions to meet the growing demand in the healthcare sector, particularly in critical disease management.
Reference
Product
Oncology – Immunospark
Reithera Srl
Rome, Italy
B
101-250 Employees
2005
Key takeaway
ReiThera is a biotech company specializing in the development and production of biopharmaceutical products for advanced therapies, including genetic vaccines for major infectious diseases. Their expertise in gene delivery technologies and GMP manufacturing positions them as a potential partner for innovative therapeutic approaches.
Reference
Core business
An ideal partner for your translational research • Reithera
We develop and produce biopharmaceutical products for advanced therapies, in order to treat several serious or life-threatening diseases.
Technologies which have been searched by others and may be interesting for you:
When exploring the CAR-T Cell Therapy industry in Italy, several key considerations come into play. Firstly, regulatory frameworks are critical; the European Medicines Agency (EMA) governs the approval and commercialization of these therapies, making adherence to stringent guidelines essential for companies. The Italian Medicines Agency (AIFA) also plays a significant role in the reimbursement process for CAR-T therapies, influencing market access and affordability. Challenges include high manufacturing costs and the complexity of treatment protocols, which can limit patient accessibility. However, the industry's growth presents substantial opportunities, particularly as Italy invests in advanced healthcare solutions and research initiatives. Collaboration between academic institutions and biotech companies is increasingly common, fostering innovation and enhancing the competitive landscape. Environmental concerns related to the production and disposal of biological materials are gaining attention, urging companies to adopt sustainable practices. On a global scale, Italy is positioned as a significant player in the CAR-T market, benefiting from its robust healthcare system and commitment to research and development. Understanding these dynamics can provide valuable insights for anyone looking to engage with or invest in this promising field within Italy.
Some interesting numbers and facts about your company results for CAR-T Cell Therapy
| Country with most fitting companies | Italy |
| Amount of fitting manufacturers | 138 |
| Amount of suitable service providers | 104 |
| Average amount of employees | 1-10 |
| Oldest suiting company | 2001 |
| Youngest suiting company | 2018 |
Some interesting questions that has been asked about the results you have just received for CAR-T Cell Therapy
What are related technologies to CAR-T Cell Therapy?
Based on our calculations related technologies to CAR-T Cell Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on CAR-T Cell Therapy?
The most represented industries which are working in CAR-T Cell Therapy are Biotechnology, Other, Medical, IT, Software and Services, Pharmaceuticals
How does ensun find these CAR-T Cell Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.